Anavex Life Sciences Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de Anavex Life Sciences ont diminué à un taux annuel moyen de -5.5%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 33.8% par an.
Informations clés
-5.48%
Taux de croissance des bénéfices
-0.18%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.04% |
| Taux de croissance des recettes | n/a |
| Rendement des fonds propres | -31.55% |
| Marge nette | n/a |
| Dernière mise à jour des bénéfices | 31 Dec 2025 |
Mises à jour récentes des performances passées
Recent updates
Nouveau récit • Mar 05
Long-Term Neurology Pipeline And Precision Medicine Work Will Support A Stronger Outlook
Catalysts About Anavex Life Sciences Anavex Life Sciences is a clinical stage biopharmaceutical company focused on oral precision medicine therapies for neurological disorders such as early Alzheimer's disease, schizophrenia related conditions, Parkinson's disease, Fragile X syndrome and Rett syndrome. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Feb 10
Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory
Summary Anavex Life Sciences faces regulatory setbacks after the EMA adopted a negative opinion of blarcamesine in Alzheimer's, citing efficacy, safety, and trial design concerns. AVXL's pipeline progress is stalled, with no ongoing clinical trials beyond Compassionate Use and scant details on future development timelines. Financially, the company holds $131.7 million in cash and minimal expenses, providing a multi-year runway but limited near-term catalysts. Given the lack of progress and regulatory limbo, I upgrade AVXL from 'Strong Sell' to 'Sell' as valuation has declined substantially. Read the full article on Seeking AlphaArticle d’analyse • May 21
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Feb 14
Anavex: Looking At Different Statistical Approaches Before EMA Opinion
Summary Anavex Life Sciences Corp.'s stock surged over 50% due to EMA's acceptance of blarcamesine for Alzheimer's review, marking a pivotal moment for the company. Despite mixed trial results, blarcamesine showed significant cognitive improvements, meeting key endpoints, though it failed in functional assessments. Financially, Anavex has a market cap of $720M and a cash runway of 8–10 quarters, with ongoing R&D expenses. Given the EMA review's potential impact, I am considering a small investment, though not right now, acknowledging AVXL stock's high volatility and associated risks. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease
Summary Anavex Life Sciences' lead drug, Blarcamesine, failed to meet one of the two co-primary endpoints in its phase 2b/3 Alzheimer's trial, casting doubt on its efficacy and approval prospects. The trial's data inconsistencies, significant toxicity, and methodological flaws undermine the drug's potential for regulatory approval by the EMA. Despite a large market potential, the likelihood of approval is low, therefore we argue Anavex's fair valuation is cash basis ($1–$2 per share). Anavex's current financials show it is well-funded, but without successful trials, its future remains bleak. Read the full article on Seeking AlphaArticle d’analyse • Dec 25
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Dec 24
Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis
Summary Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers, with a market cap just under $1bn and stock up 90% YTD. Other biotech firms in the AD space like Cassava, Annovis, and Alector have faced significant setbacks, including failed trials and financial struggles. Despite my previous “Sell” rating, Anavex stock has shown resilience, up over 350% in five years, and 90% year-to-date, contrasting with peers' declining fortunes. Biogen and Lilly's approved amyloid-targeting drugs have limited efficacy and safety risks, highlighting the need for alternative Alzheimer's treatments like Anavex's approach. Unfortunately, I see too many red flags waving to endorse AVXL, but time will tell — the European approval shot is a major catalyst upcoming that I am bearish on. Read the full article on Seeking AlphaSeeking Alpha • Dec 08
Anavex: EU Approval Application Is A Precipitous Moment
Summary Anavex (AVXL) has submitted an MAA for blarcamesine in Alzheimer's, a critical step that puts their molecule under regulatory scrutiny. Despite past trial failures, Anavex's Phase 2b/3 trial showed significant cognitive improvements, though it failed one co-primary endpoint. Data inconsistencies and lack of US clinical trials raise concerns, but EU approval could still be possible. The EMA's decision on blarcamesine, expected by mid-2025, will be crucial, especially given the FDA's controversial approval of Biogen's Aduhelm. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
Summary Panax ginseng shows the highest effectiveness in treating Alzheimer's because it inhibits nitro-oxidative stress, scavenges peroxynitrite, and reverses part of its damage, leading to sustained cognitive improvements over two years. Anavex's Blarcamesine may slow mild Alzheimer's progression due to its antioxidant capacity, with results from a 96-week trial potentially aiding regulatory approval. Cassava Sciences' Simufilam's effectiveness is limited to one year for mild Alzheimer's, with no residual effects after discontinuation, and mixed results in combined mild and moderate groups. Safety profiles differ, with simufilam being safer but less effective long-term compared to blarcamesine. The latter may cause confusion and dizziness. Read the full article on Seeking AlphaSeeking Alpha • Nov 05
Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Summary On Thursday, Oct. 31, Anavex announced new data from their phase 2b/3 Alzheimer's trial, which was presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 conference. This news sent the stock soaring, with an ~16% increase in price. I take a look at the new data and share my thoughts here. Read the full article on Seeking AlphaSeeking Alpha • Oct 08
Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Summary Anavex's lead drug, ANAVEX2-73, failed its Phase 2/3 trial for Rett syndrome, and Alzheimer's data showed questionable efficacy and concerning safety issues. The company's financial health is stable with a cash runway of about four years, but operational risks and rising costs are significant concerns. AVXL's decision to seek EU approval for ANAVEX2-73 based on limited data is perplexing, especially given the stringent regulatory environment. The overall recommendation is a "strong sell" due to poor clinical results, overvaluation, and high operational and financial risks. Read the full article on Seeking AlphaSeeking Alpha • Jul 29
Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Summary Anavex Life Sciences shared latest data from its SIGMAR-protein targeting drug Blarcamesine yesterday, in Alzheimer's Disease. On a positive note, data showed clinical decline was slowed by 38.5% in the 50-mg arm, and 34.6% in the 30mg arm. On the negative side, the secondary endpoint was not met, and there was a seemingly high number of study withdrawals. Anavex wants to file for approval of Blarcamesine in Europe this year, and also with the FDA in the US. My suspicion is that the FDA will insist on further studies, and EMA may not be convinced on efficacy and safety. Read the full article on Seeking AlphaArticle d’analyse • Jul 17
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Article d’analyse • Apr 01
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Article d’analyse • Sep 19
Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Anavex Life Sciences gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 25 | 0 | -40 | 13 | 31 |
| 30 Sep 25 | 0 | -46 | 14 | 37 |
| 30 Jun 25 | 0 | -48 | 13 | 40 |
| 31 Mar 25 | 0 | -47 | 11 | 42 |
| 31 Dec 24 | 0 | -46 | 12 | 41 |
| 30 Sep 24 | 0 | -43 | 11 | 39 |
| 30 Jun 24 | 0 | -42 | 11 | 38 |
| 31 Mar 24 | 0 | -41 | 12 | 36 |
| 31 Dec 23 | 0 | -43 | 12 | 38 |
| 30 Sep 23 | 0 | -48 | 12 | 41 |
| 30 Jun 23 | 0 | -52 | 13 | 42 |
| 31 Mar 23 | 0 | -53 | 13 | 41 |
| 31 Dec 22 | 0 | -50 | 13 | 38 |
| 30 Sep 22 | 0 | -48 | 13 | 35 |
| 30 Jun 22 | 0 | -45 | 12 | 32 |
| 31 Mar 22 | 0 | -43 | 11 | 32 |
| 31 Dec 21 | 0 | -41 | 11 | 29 |
| 30 Sep 21 | 0 | -38 | 9 | 28 |
| 30 Jun 21 | 0 | -32 | 8 | 24 |
| 31 Mar 21 | 0 | -28 | 7 | 22 |
| 31 Dec 20 | 0 | -28 | 6 | 22 |
| 30 Sep 20 | 0 | -26 | 6 | 21 |
| 30 Jun 20 | 0 | -26 | 6 | 20 |
| 31 Mar 20 | 0 | -26 | 6 | 20 |
| 31 Dec 19 | 0 | -26 | 7 | 20 |
| 30 Sep 19 | 0 | -26 | 7 | 20 |
| 30 Jun 19 | 0 | -26 | 7 | 20 |
| 31 Mar 19 | 0 | -23 | 7 | 16 |
| 31 Dec 18 | 0 | -20 | 7 | 14 |
| 30 Sep 18 | 0 | -17 | 6 | 11 |
| 30 Jun 18 | 0 | -17 | 6 | 11 |
| 31 Mar 18 | 0 | -18 | 6 | 12 |
| 31 Dec 17 | 0 | -14 | 5 | 9 |
| 30 Sep 17 | 0 | -13 | 5 | 9 |
| 30 Jun 17 | 0 | -15 | 7 | 8 |
| 31 Mar 17 | 0 | -13 | 7 | 7 |
| 31 Dec 16 | 0 | -14 | 6 | 8 |
| 30 Sep 16 | 0 | -15 | 8 | 7 |
| 30 Jun 16 | 0 | -14 | 8 | 4 |
| 31 Mar 16 | 0 | -16 | 8 | 4 |
| 31 Dec 15 | 0 | -15 | 8 | 3 |
| 30 Sep 15 | 0 | -12 | 5 | 2 |
Des revenus de qualité: AVXL n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: AVXL n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: AVXL n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 5.5% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de AVXL au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: AVXL n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( 43% ).
Rendement des fonds propres
ROE élevé: AVXL a un retour sur capitaux propres négatif ( -31.55% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/26 01:53 |
| Cours de l'action en fin de journée | 2026/05/26 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/09/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Anavex Life Sciences Corp. est couverte par 9 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Caroline Palomeque | Berenberg |
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Jason Kolbert | D. Boral Capital LLC. |